Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma
BMC Cancer May 12, 2021
Xu Y, Wu Z, Ye W, et al. - In this retrospective analysis, researchers analyzed locally advanced nasopharyngeal carcinoma (LANPC) patients receiving induction chemotherapy (IC) followed by concurrent chemoradiation therapy (CCRT), to determine the combined predictive value of serum uric acid (SUA) and tumor response to IC in this population. Participants included 341 LANPC cases managed with IC + CCRT. In multivariable analysis, SUA concentration following two cycles of IC was revealed as an independent prognostic factor for overall survival (OS) but of borderline significance for progression-free survival (PFS) and distant metastasis-free survival (DMFS). A better OS, PFS, and DMFS was noted in LANPC patients with satisfactory tumor response and a high SUA level following two cycles of IC, relative to those with unsatisfactory tumor response and a low SUA level. Overall, predictive value of SUA level as well as tumor response to two cycles of IC was evident for LANPC patients managed with IC plus CCRT. For patients with a low SUA concentration and unsatisfactory tumor response to two cycles of IC, more aggressive treatment strategies are advised.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries